Overcoming Deadly Diseases

Phase 3 ACTION Study of ONC201 (dordaviprone) Now Enrolling

Improving and Extending Lives

Chimerix’s mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases.  Learn more about our approach to investing in novel drug candidates that meaningfully improve the probability of survival and the collaborative team driving the development of these promising new therapies.

Recent Publication in Journal of Clinical Oncology

To access our most recent publication ONC201 (dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma, please click here


view all

Edit This